EULAR Highlights 2017
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
FRI0252<br />
FRI0253<br />
FRI0254<br />
FRI0313<br />
FRI0321<br />
FRI0336<br />
FRI0673<br />
Saturday June 17, 2016<br />
POSTERS<br />
SAT0026<br />
SAT0083<br />
SAT0170<br />
SAT0181<br />
SAT0182<br />
SAT0183<br />
<br />
SAT0184<br />
SAT0189<br />
SAT0192<br />
SAT0193<br />
SAT0194<br />
<br />
Summary of Neutropenia in Patients with Rheumatoid Arthritis Treated<br />
with Sirukumab in the SIRROUND Phase 3 Clinical Trials<br />
Patient-Reported Outcomes in Patients with Rheumatoid Arthritis<br />
Treated with Subcutaneous Tocilizumab Compared with Placebo or<br />
Intravenous Tocilizumab in Combination with csDMARDs<br />
Efficacy of Tocilizumab for Suppressing Radiographic Progression of<br />
Cervical Lesions in Patients with Rheumatoid Arthritis Comparison<br />
with Methotrexate Treatment; Two Years of Follow-Up ~A Multicenter<br />
Registry Study ~<br />
The Efficacy and Safety of Tocilizumab Therapy in Patients With<br />
Polymyalgia Rheumatica who were Resistant or Intolerant to<br />
Glucocorticoids and Additional Methotrexate<br />
Circulating Il-6 and Other Metabolic Biomarkers Comparing Effects<br />
of Modified-Release Prednisone (MR) and Immediate-Release<br />
Prednisolone (IR) in new GCA<br />
Efficacy of Tocilizumab in 31 Patients with Giant Cell Arteritis<br />
Clinical Remission in Tocilizumab-Using Rheumatoid Arthritis Patients<br />
can be Overestimated: A Cross Sectional Study Using Ultrasound<br />
Sonography<br />
Signalling Through Insulin-Like Growth Factor 1 Receptor Contributes<br />
to IL-6 Production and Supports T Cell Dependent Inflammation in<br />
Rheumatoid Arthritis<br />
Tocilizumab Induced Clinical Remission in Rheumatoid Arthritis had<br />
More Residual Doppler Signals in Comparison With Other Biologics<br />
B-Cell Phenotype and IGD-CD27- Memory B Cells are Affected by TNF-<br />
Inhibitors and Tocilizumab Treatment in Rheumatoid Arthritis<br />
Low Dose Interleukin-2 Combined with Tocilizumab Selectively<br />
Increases Regulatory T Cells Helping Refractory Rheumatoid Arthritis<br />
Patients Achieve Remission More Rapidly<br />
Sirukumab Leads to Significant and Clinically Meaningful Improvements<br />
in Health-Related Quality of Life That Meet or Exceed Normative Values<br />
in Patients With Rheumatoid Arthritis Refractory to TNF Inhibitors in Post<br />
Hoc Analyses of a Phase 3 Trial<br />
Clinical Remission in Subjects With Rheumatoid Arthritis Treated With<br />
Subcutaneous Tocilizumab as Monotherapy or in Combination With<br />
Methotrexate Or Other Synthetic Dmards: A Real-World Clinical Trial<br />
(TOSPACE)<br />
Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients With<br />
Reduced Doses of Intravenous Tocilizumab<br />
Factors Influencing the Prescription of Tocilizumab Alone or in<br />
Combination With DMARDs in Rheumatoid Arthritis Patients in a Real<br />
Life Setting. Pooled Analysis of 3 Observational Studies<br />
Sarilumab Suppresses Thrombosis-Related Gene Expression in<br />
Circulating Blood Cells in MTX-IR and TNF-IR Patients With Active<br />
Rheumatoid Arthritis<br />
RA Patients With Inflammatory Anemia Benefit From Increased<br />
Hemoglobin and Decreased Fatigue Under Tocilizumab Therapy<br />
Sirukumab Integrated Safety in Rheumatoid Arthritis Patients: Analysis<br />
of the SIRROUND Phase 3 Data<br />
SAT0198 Tocilizumab for the Management of Rheumatoid Arthritis:<br />
Discontinuation Due to Inefficacy and Toxicity – Experience from a Large<br />
Teaching Hospital<br />
SAT0199 Subcutaneous Tocilizumab Monotherapy or Combined With a csDMARD<br />
in Patients With Rheumatoid Arthritis: Tozura, a Pooled Analysis of Phase<br />
IV Studies In 22 Countries<br />
SAT0202 Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab<br />
Monotherapy in Patients With Active Rheumatoid Arthritis in the Phase 3<br />
Monarch Study, Including Subpopulations<br />
SAT0203 Significance of Extension of Tocilizumab Infusion Intervals From 4<br />
Weeks to 6 Weeks in RA Patients Who Had Shown Good Response to 4<br />
Week Intervals<br />
SAT0206 Retention of Tocilizumab as Monotherapy Versus TNF Inhibitors With<br />
Conventional Synthetic DMARDs in Rheumatoid Arthritis Patients With<br />
Inadequate Response to TNF Inhibitors: A Study From The TOCERRA<br />
Collaboration<br />
SAT0209 Observational Study on the Effects of IL-6 Inhibitor Therapy on Myostatin<br />
in Patients With Rheumatoid Arthritis<br />
SAT0212 Sarilumab Dose Reduction in an Open-Label Extension Study in RA<br />
Patients With Inadequate Response to TNF Inhibitors<br />
SAT0214 An Analysis of Increasing Spacing Time for the Intravenous<br />
Administration of Tocilizumab in Patients With Rheumatoid Arthritis<br />
SAT0218 Effect of Tocilizumab in DMARD-Naïve Early Rheumatoid Arthritis Patients<br />
on Health-Related Quality Of Life: Results of the U-ACT-Early Trial<br />
SAT0524 Utility of Tocilizumab in Clinical Manifestations of Erosive Osteoarthrosis<br />
of Hands<br />
Regional Hospital ISSTE Puebla, México<br />
Chairman’s picks